Thomas F Tucker

US Patent:

20190389909, Dec 26, 2019

Filed:

Jun 20, 2019

Appl. No.:

16/446940

Inventors:

- Rahway NJ, US
Hubert B. Josien - Jersey City NJ, US
Thomas Joseph Tucker - North Wales PA, US
Angela Dawn Kerekes - Plainfield NJ, US
Ling Tong - Warren NJ, US
Abbas M. Walji - Lansdale PA, US
Anilkumar G. Nair - RAHWAY NJ, US
Elisabetta Bianchi - Rome, IT
Danila Branca - Pomezia, IT
Chengwei Wu - Ambler PA, US
Yusheng Xiong - Plainsboro NJ, US
Sookhee Nicole HA - Warren NJ, US
Jian Liu - Edison NJ, US
Sobhana Babu Boga - Karnataka, IN

International Classification:

C07K 7/64
A61P 3/06

Abstract:

Disclosed are compounds of Formula I, or a salt thereof:where A, B, D, X, R, Rand Rare as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

US Patent:

20170189441, Jul 6, 2017

Filed:

Nov 3, 2014

Appl. No.:

15/033715

Inventors:

Steven L. COLLETTI - Kenilworth NJ, US
Thomas J. TUCKER - West Point PA, US
David M. TELLERS - West Point PA, US
Boyoung KIM - Lansdale PA, US
Rob BURKE - Philadelphia PA, US
Kathleen B. CALATI - Rahway NJ, US
Matthew G. STANTON - Marlton NJ, US
Rubina G. PARMAR - Harleysville PA, US
Jeffrey G. AARONSON - Philadelphia PA, US
Weimin WANG - Churchville PA, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/7125
A61K 38/10
A61K 38/16
A61K 31/713

Abstract:

Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)-(G); wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)-(L)-(G); wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.